Research in many cancers has uncovered changes in metabolic pathways that control
tumour energetics and biosynthesis, so-called metabolic reprogramming. Studies in clear …

Abstract On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-
class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) …

Dysregulated metabolism is a hallmark of cancer, manifested through alterations in
metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell …

Abstract Inactive von Hippel-Lindau (VHL) is linked to metabolic reprogramming and plays
pivotal roles in the pathogenesis of clear cell renal cell carcinoma (ccRCC). Here, we …

Deregulation of angiogenesis–the growth of new blood vessels from an existing vasculature–
is a main driving force in many severe human diseases including cancer. As such, tumor …

Angiogenesis is involved in physiological and pathological processes in the body. Tumor
angiogenesis is a key factor associated with tumor growth, progression, and metastasis …

Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian
target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did …

Recent studies have established that tumors can reprogram the pathways involved in
nutrient uptake and metabolism to withstand the altered biosynthetic, bioenergetics and …

Vascular endothelial growth factor (VEGF) is a homodimeric glycoprotein with a molecular
weight of approximately 45 kDa. It is the key mediator of angiogenesis (the formation of new …

Although patients with advanced refractory solid tumors have poor prognosis, the clinical
development of targeted protein kinase inhibitors offers hope for the future treatment of many …